Global pharmaceutical giant Pfizer’s domestic market share of its top seller Lipitor slipped nearly 15 percent in just one month after local drugmakers released generics of the cholesterol-lowering pill in June. But the head of the Korean operation isn’t sweating over it.
Earlier in June, 5 generic firm, got positive opinion from Korean court on Lipitor launch. The court thwarted innovator’s patent ever greening attempts, as reported earlier by IPPHARMADOC Here
Full story Here
Earlier in June, 5 generic firm, got positive opinion from Korean court on Lipitor launch. The court thwarted innovator’s patent ever greening attempts, as reported earlier by IPPHARMADOC Here
Full story Here
No comments:
Post a Comment